Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, today announced that the company will present recent advances in Celyad’s pipeline at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 16–19, 2018, in Chicago.
Poster presentations will highlight the recent developments of Celyad’s pipeline in autologous and allogeneic platforms to address cancers. The oral presentation will give updated data of the ongoing THINK Phase 1 trial with the case report of a CYAD-01 associated complete response in one relapsed/refractory AML patient, including observations concerning the modulation of systemic chemokines during the course of treatment.
David Gilham, VP of Research and Development at Celyad, commented: ‘Our presentations at the 2018 meeting of the ASGCT will share our increasing knowledge around our lead NKG2D CAR T cell candidate along with discussing our pipeline including the B7H6 CAR T program and our allogeneic platform. These presentations are the culmination of an intensive level of activity within our R&D group. We anticipate that this will lead to a series of assets that will enter clinical stage testing during 2019.’
Presentation Details:
| Title | Early Signs of Clinical Activity in AML Patients Receiving NKG2D CAR-T Cell Therapy in the Absence of Pre-Conditioning Chemotherapy: An Alternative Strategy to CAR-T Cell TherapyLink |
| Number | 967 |
| Category | Cancer-Immunotherapy, Cancer Vaccines |
| Session | 412 Advancements in T Cell-Based Therapies |
| Session Date & Time | Saturday, May 19, 2018, 11:00 AM CDT |
| Location | Continental Ballroom ABC |
Posters Details:
| Poster title | Functional screening of a B7H6 specific chimeric antigen receptor (CAR)Link |
| Poster Number | 123 |
| Category | Cancer – Immunotherapy, Cancer Vaccines I |
| Session | Exhibit Hall Welcome Reception & Poster Session I |
| Session Date & Time | Wednesday, May 16, 2018, 5:30 PM CDT |
| Location | Stevens Salon C, D |
| Poster Title | Overcoming target-driven fratricide for CAR-T cell therapyLink |
| Poster Number | 119 |
| Category | Cancer-Immunotherapy, Cancer Vaccines |
| Session | Exhibit Hall Welcome Reception & Poster Session I |
| Session Date & Time | Wednesday, May 16, 2018, 5:30 PM CDT |
| Location | Stevens Salon C, D |
| //Poster Title | Expression of a TIM8 peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approachLink |
| Poster Number | 457 |
| Category | Cell Therapies |
| Session | Exhibit Hall Networking Reception & Poster Session II |
| Session Date & Time | Thursday, May 17, 2018, 5:15 PM CDT |
| Location | Stevens Salon C, D |
